Efficacy and safety of ticagrelor use in pre-hospital setting

Affiliations

¹ Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, Poland; Polish Society of Disaster Medicine, Warsaw, Poland; Maria Sklodowska-Curie Białystok Oncology Centre, Białystok, Poland. Electronic address: lukasz.szarpak@gmail.com.
² 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
³ Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.
⁴ Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands; 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
⁵ Polish Society of Disaster Medicine, Warsaw, Poland.

Meta-Analysis

Lukasz Szarpak et al. Am J Emerg Med. 2022 Feb.

. 2022 Feb:52:265-266.

doi: 10.1016/j.ajem.2021.04.031. Epub 2021 Apr 18.

¹ Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, Poland; Polish Society of Disaster Medicine, Warsaw, Poland; Maria Sklodowska-Curie Białystok Oncology Centre, Białystok, Poland. Electronic address: lukasz.szarpak@gmail.com.
² 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
³ Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.
⁴ Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands; 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
⁵ Polish Society of Disaster Medicine, Warsaw, Poland.

No abstract available

Keywords: Acute coronary syndrome; Antiplatelet treatment; Outcome; P2Y12; Prehospital; Ticagrelor.

Conflict of interest statement

Declaration of Competing Interest None.